AlphAIAlphAI — Financial news for AI agents
investing.com$LQDA

Jefferies raises Liquidia stock price target to $62 on revenue growth

Jefferies raised its price target on Liquidia (NASDAQ:LQDA) to $62 from $55, maintaining a Buy rating. The company reported Q3 revenue of $222.7M, up 31% sequentially, with a GAAP EPS loss of $2.64 due to a $389.7M settlement charge. Adjusted EBITDA rose to $140.5M, and the stock has returned 76% over the past year. Jefferies expects 2027 revenue to reach $910M, citing strong growth in pulmonary arterial hypertension treatments.

Original reporting
investing.com
Published Nov 10, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LQDA
Bullish
high confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LQDABullishMed
01

Why it matters

The earnings beat and higher target are likely to attract buying interest, though the settlement loss remains a downside risk.

02

Market read

Fresh earnings data and analyst upgrade provide a new trading catalyst for LQDA.

03

What to watch

Potential future litigation risk and reliance on a single product line may limit upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Liquidia Technologies (NASDAQ:LQDA) reported Q3 results with strong revenue growth but a large settlement charge, prompting Jefferies to raise its price target.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

Jefferies raised its price target on Liquidia Technologies to $62 and reported Q3 revenue of $222.7M, a 31% sequential increase.

Expected impact

likely upward pressure as the market prices in the higher target and revenue beat

Evidence & confidence

The new target and better‑than‑expected sales provide a fresh catalyst for buying pressure.

Market effects

Sector

Positive for the pulmonary arterial hypertension niche and biotech sector as earnings beat may lift peers.

Regional

U.S. biotech stocks could see modest gains.

Global

Limited to investors tracking US‑listed biotech firms.

Counterpoint

What could challenge this read

The $389.7M settlement charge and GAAP loss could weigh on the stock despite revenue growth.

Key entities

  • company
    Liquidia Technologies

    Biotech firm focused on pulmonary arterial hypertension therapies.

  • analyst
    Jefferies

    Investment bank that raised the price target to $62.

Read at source← All news

StoryLiquidia reports Q3 2026 loss driven by $389.7 M litigation settlement but revenue beats estimates

Also covered by

2 outlets

Related articles

$LQDAMed

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.

investing.com
$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K